Literature DB >> 11578972

Receptor for age (RAGE) is a gene within the major histocompatibility class III region: implications for host response mechanisms in homeostasis and chronic disease.

A M Schmidt1, D M Stern.   

Abstract

Receptor for AGE (RAGE), a member of the immunoglobulin superfamily, was first identified as a specific cell surface interaction site for Advanced Glycation Endproducts, or AGEs. AGEs, the products of nonenzymatic glycation/oxidation of proteins/lipids, accumulate in natural aging and disorders such as diabetes, renal failure and amyloidoses. Interaction of AGEs with RAGE has been linked to chronic inflammatory and vascular dysfunction that characterizes the chronic complications of these disorders. Recent studies have indicated that RAGE is a multiligand receptor, serving as a specific cell surface, signal transducing receptor for amphoterin, a molecule with implications for neurite outgrowth in neuronal development and in tumor cell proliferation and spread. RAGE is also a receptor for amyloid-beta peptide, whose interaction with neuronal and microglial RAGE within the CNS is linked to sustained inflammation and neuronal toxicity and cell death. RAGE also serves as a signal-transducing receptor for EN-RAGEs, and related members of the S100/calgranulin family of proinflammatory cytokines; consequences of this interaction include initiation and propagation of inflammatory responses. Consistent with an important role for ligand-RAGE interaction in these settings, blockade of RAGE suppresses chronic cellular activation and dysfunction in murine models of diabetic complications, inflammation and tumor proliferation and metastasis. Taken together, an new paradigm is emerging which links RAGE, a gene encoded within the Major Histocompatibility Complex (MHC) Class III regions, to central host response mechanisms in homeostasis and chronic disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11578972     DOI: 10.2741/schmidt

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  24 in total

1.  Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response.

Authors:  Birgit Liliensiek; Markus A Weigand; Angelika Bierhaus; Werner Nicklas; Michael Kasper; Stefan Hofer; Jens Plachky; Herman-Josef Gröne; Florian C Kurschus; Ann Marie Schmidt; Shi Du Yan; Eike Martin; Erwin Schleicher; David M Stern; G ünterJ Hämmerling G; Peter P Nawroth; Bernd Arnold
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

2.  Advanced glycation end product recognition by the receptor for AGEs.

Authors:  Jing Xue; Vivek Rai; David Singer; Stefan Chabierski; Jingjing Xie; Sergey Reverdatto; David S Burz; Ann Marie Schmidt; Ralf Hoffmann; Alexander Shekhtman
Journal:  Structure       Date:  2011-05-11       Impact factor: 5.006

Review 3.  AGE restriction in diabetes mellitus: a paradigm shift.

Authors:  Helen Vlassara; Gary E Striker
Journal:  Nat Rev Endocrinol       Date:  2011-05-24       Impact factor: 43.330

4.  Diabetes and cancer: Looking at the multiligand/RAGE axis.

Authors:  Armando Rojas; Ileana González; Erik Morales; Ramón Pérez-Castro; Jacqueline Romero; Héctor Figueroa
Journal:  World J Diabetes       Date:  2011-07-15

5.  Pentoxifylline alleviates high-fat diet-induced non-alcoholic steatohepatitis and early atherosclerosis in rats by inhibiting AGE and RAGE expression.

Authors:  Jing Wu; Miao-yun Zhao; Hao Zheng; Hua Zhang; Ying Jiang
Journal:  Acta Pharmacol Sin       Date:  2010-09-13       Impact factor: 6.150

6.  Aging alters mRNA expression of amyloid transporter genes at the blood-brain barrier.

Authors:  Doreen Osgood; Miles C Miller; Arthur A Messier; Liliana Gonzalez; Gerald D Silverberg
Journal:  Neurobiol Aging       Date:  2017-05-19       Impact factor: 4.673

7.  Posttranslationally modified proteins as mediators of sustained intestinal inflammation.

Authors:  Martin Andrassy; John Igwe; Frank Autschbach; Christian Volz; Andrew Remppis; Markus F Neurath; Erwin Schleicher; Per M Humpert; Thoralf Wendt; Birgit Liliensiek; Michael Morcos; Stephan Schiekofer; Kirsten Thiele; Jiang Chen; Rose Kientsch-Engel; Ann-Marie Schmidt; Wolfgang Stremmel; David M Stern; Hugo A Katus; Peter P Nawroth; Angelika Bierhaus
Journal:  Am J Pathol       Date:  2006-10       Impact factor: 4.307

Review 8.  Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions.

Authors:  Anusha Jayaraman; Christian J Pike
Journal:  Curr Diab Rep       Date:  2014-04       Impact factor: 4.810

Review 9.  Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease.

Authors:  Susan J Zieman; David A Kass
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Serum albumin induces iNOS expression and NO production in RAW 267.4 macrophages.

Authors:  Michael Poteser; Ichiro Wakabayashi
Journal:  Br J Pharmacol       Date:  2004-08-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.